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OBJECTIVE: Ischemic stroke may result from transient or permanent reductions of regional cerebral blood flow.
Polymorphonuclear neutrophils have been described as the earliest inflammatory cells to arrive in ischemic
tissue. CXCR1/2 receptors are involved in the recruitment of these cells. However, the contribution of these
chemokine receptors during transient brain ischemia in mice remains poorly understood. In this work, we
investigated the effects of reparixin, an allosteric antagonist of CXCR1/2 receptors, in a model of middle
cerebral artery occlusion and reperfusion in mice.
METHODS: C57BL/6J male mice treated with reparixin or vehicle were subjected to a middle cerebral artery
occlusion procedure 1 h after the treatment. Ninety minutes after ischemia induction, the monofilament that
prevented blood flow was removed. Twenty-four hours after the reperfusion procedure, behavioral changes,
including motor signs, were analyzed with the SmithKline/Harwell/Imperial College/Royal Hospital/Phenotype
Assessment (SHIRPA) battery. The animals were sacrificed, and brain tissue was removed for histological and
biochemical analyses. Histological sections were stained with hematoxylin and eosin, neutrophil infiltration was
estimated by myeloperoxidase activity and the inflammatory cytokine IL-1b was measured by ELISA.
RESULTS: Pre-treatment with reparixin reduced the motor deficits observed in this model of ischemia and
reperfusion. Myeloperoxidase activity and IL-1b were reduced in the reparixin-treated group. Histological
analysis revealed that ischemic injury was also attenuated by reparixin pre-treatment.
CONCLUSIONS: Our results suggest that the blockade of the CXCR1/2 receptors by reparixin promotes
neuroprotective effects by reducing the levels of polymorphonuclear infiltration in the brain and the tissue
damage associated with middle cerebral artery occlusion and reperfusion.
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& INTRODUCTION
Ischemic stroke may result from transient or permanent
reductions of regional cerebral blood flow (1). In humans,
stroke is the second most common cause of death worldwide
(2) and often occurs in the territory supplied by the middle
cerebral artery (3). Inflammatory processes have been
implicated in the pathophysiology of cerebral ischemia,
involving the recruitment and influx of leukocytes from the
circulation to the ischemic brain tissue.
In the early stages of ischemia, polymorphonuclear
neutrophils (PMNs) are the main type of infiltrating cells.
Several studies report the later presence of monocytes/
macrophages, activation of resident brain cells and the
expression of proinflammatory cytokines, chemokines and
adhesion molecules in the injured brain (4). Leukocyte
infiltration, especially of PMNs, seems to play a deleterious
role during an ischemic event in the central nervous system
(5). PMNs are a potential source of radical oxygen species,
proteinases and cytokines that may contribute to the brain
injury (6). Furthermore, strategies affecting the recruitment of
PMNs are of great interest for controlling various inflamma-
tory diseases. Several authors have postulated that the
expression of certain chemokines, mainly CXC ligand 8
(CXCL8) in humans and CXCL1 and CXCL2 in rodents, by
central nervous system cells is required for PMN accumula-
tion and activation (7). Furthermore, human patients exhibit
increased circulating levels of CXCL8 following stroke (8).
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In the last decade, several studies have suggested that
anti-inflammatory strategies could be of paramount impor-
tance to prevent brain damage following cerebral ischemia
(9,10). Indeed, anti-chemokine approaches successfully
conferred neuroprotection in rodent models of brain
ischemia (11-13).
Reparixin is a chemical derivative of phenyl propionic
acids that acts as noncompetitive allosteric antagonist of the
chemokine receptors CXCR1 and CXCR2, which bind to the
chemokines CXCL1 (previously known as KC) and CXCL2
(previously known as MIP-2). Therefore, the aim of this
study was to investigate the effect of reparixin on
inflammatory and behavioral outcomes in a model of
middle cerebral artery occlusion and reperfusion (MCAo)
in mice.
& MATERIAL AND METHODS
Animals: Male C57BL/6J mice (8-10 weeks old/20-25 g)
obtained from the Animal Care Facilities of the Institute of
Biological Science (ICB-UFMG) were maintained in a
temperature controlled room (24¡1 C˚) under standard
laboratory conditions with free access to food and water
and a 12-h light/12-h dark cycle (lights on at 7 a.m.). All
experiment procedures were conducted in accordance with
the Animal Ethics Committee (CETEA-UFMG).
Drugs: Reparixin (30 mg/kg – Dompe´ Pharma, L’Aquila,
Italy), a CXCR1/2 allosteric antagonist, was dissolved in
saline and administered subcutaneously.
Transient focal cerebral ischemia: Mice were anesthe-
tized by intraperitoneal injection of ketamine hydrochloride
(150 mg/kg) and xylazine (10 mg/kg). The surgical proce-
dure was performed on a warming mantle with all animals
spontaneously breathing. Transient focal cerebral ischemia
was induced by MCAo, using the method previously
described for rats by Longa et al., 1989 (10). Briefly, a
blunted silicon tip (Silon2 APS Fluido, Petro´polis, Brazil)
and a 5-0 nylon monofilament catalyst (Silon2 APSC,
Petro´polis, Brazil) were advanced to the level of the carotid
bifurcation via the internal carotid artery until light
resistance was felt. The monofilament was removed after
90 minutes of occlusion. In the sham group, the arteries
were visualized but not disturbed.
SHIRPA screening test: The primary SmithKline/
Harwell/Imperial College/Royal Hospital/Phenotype
Assessment (SHIRPA) screen consists of a wide range of
tests, organized into the following five functional categories:
neuropsychiatric state (i.e., spontaneous activity, transfer
arousal, touch escape, positional passivity, biting, fear,
irritability, aggression, vocalizations), motor behavior (i.e.,
body position, tremor, locomotor activity, pelvic elevation,
gait, tail elevation, trunk curl, limb grasping, wire maneu-
ver, negative geotaxis), reflex and sensory function (i.e.,
startle response, visual placing, pinna reflex, corneal reflex,
toe pinch, righting reflex), autonomic function (i.e., respira-
tory rate, defecation, urination, palpebral closure, piloerec-
tion, skin color, heart rate, lacrimation, salivation, body
temperature) and muscle tone and strength (i.e., grip
strength, body tone, limb tone, abdominal tone). The
SHIRPA provides a basic behavioral and functional profile
through the observational assessment of individual perfor-
mance (14). All measures were performed in a Plexiglas
square arena (40 cm6 40 cm6 30 cm).
Experimental procedures: The subcutaneous administra-
tion of reparixin (30 mg/kg) was performed 60 minutes
before cerebral ischemia induction (15). The animals were
divided into the following three experimental groups: Sham
(i.e., the group in which the arteries were visualized, but
there was no occlusion of the middle cerebral artery),
Vehicle (i.e., the group pre-treated with the vehicle,
phosphate buffer solution, 60 minutes before MCAo) and
Reparixin (i.e., the group pre-treated with the drug 60
minutes before MCAo). To evaluate neurological signs
secondary to MCAo, the animals were assessed with the
SHIRPA battery 24 h after reperfusion (16). Immediately
after behavioral testing, all animals were sacrificed, and the
whole brain was removed for biochemical and histological
analyses. Neutrophil infiltration in the brain was estimated
by myeloperoxidase activity test (MPO), and the results
were expressed in relative units. The concentration of IL-1b
was measured in brain tissue using a commercially
available enzyme-linked immunosorbent assay (ELISA),
according to the manufacturer’s instructions (Duo-Set Kits;
R&D Systems, Minneapolis, MN). For histological analysis,
a brain fragment was preserved in 10% buffered formalin.
Sections (4 mm thick) were subject to routine hematoxylin
and eosin staining. Ischemia/reperfusion-induced lesions
and the infiltration of inflammatory cells were analyzed
qualitatively.
Statistical analysis: Data are represented as the means¡
SEM. One-way ANOVA followed by the Newman-Keuls
post-hoc test was used for multiple comparisons. The
statistical significance was set at p,0.05.
& RESULTS
When subjected to MCAo, vehicle-treated mice exhibited
higher MPO activity, an index of PMN infiltration in the
brain, in comparison with the sham animals. Reparixin
significantly prevented the increase of MPO induced by
MCAo (Figure 1).
Vehicle-treated animals subjected to the MCAo proce-
dures also displayed higher brain levels of IL1-b compared
to sham mice. Similar to the MPO results, pretreatment with
Figure 1 - Reparixin reduces neutrophil activity in the brain after
middle cerebral artery occlusion/reperfusion (MCAo) in mice. The
figure shows myeloperoxidase (MPO) activity in mice not
subjected to MCAo (Sham) or subjected to MCAo with pre-
administration of vehicle (Vehicle) or reparixin (30 mg/kg, s.c.) 60
minutes before MCAo procedures. The results are expressed as
the means ¡ SEM (n = 6). * p,0.05 compared to Sham group.
# p,0.05 compared to vehicle. (ANOVA followed by Newman-
Keuls posthoc test).
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reparixin significantly reduced the levels of this inflamma-
tory cytokine (Figure 2).
The ischemia/reperfusion procedure induced an exten-
sive hemorrhagic necrosis in the brain (Figures 3 A-D). This
lesion was circumscribed by inflammatory cells, mainly
PMNs, surrounded by degenerative tissue (Figures 3 C and
D). Corroborating the MPO and IL1-b results, reparixin
treatment attenuated the ischemia/reperfusion-induced
lesions and the infiltration of inflammatory cells (Figures 3
E and F).
Consistent with these pathological results, the MCAo
procedure induced motor impairment, which was attenu-
ated by pretreatment with reparixin (Figure 4). Other
SHIRPA categories did not change after MCAo.
& DISCUSSION
In this work, we demonstrated that the inhibition of
CXCR1/2 receptors by reparixin protected the brain after
MCAo. The blockade of CXCR1/2 receptors attenuated not
only the structural changes in the ischemic brain but also the
corresponding behavioral consequences of the brain injury.
Tissue damage after ischemia is mediated through several
mechanisms, including hypoxia and inflammatory res-
ponses (17). The latter is particularly relevant in the context
of reperfusion, in which PMNs infiltrate ischemic/reper-
fused organs, such as the brain, lung and intestine (10, 18,
19). Once in the tissue, neutrophils release enzymes from
their granules that may cause serious damage to the
inflamed tissue. The peak of PMN infiltration occurs 24 h
after the ischemia (20); this was the time point chosen to
perform the analyses for this work.
Strategies against the recruitment of PMNs have been
associated with protective effects in ischemia/reperfusion
models (21,19). Considering the role of CXCR1 and CXCR2
in PMN recruitment, their blockade could theoretically
protect the brains of mice subjected to MCAo (10). Reparixin
is a compound that inhibits the effects of CXCL1 and CXCL2
by allosteric modulation of the CXCR1 and CXCR2
receptors. In rats, reparixin reduced brain PMN infiltration
and the associated tissue damage in a cerebral ischemia/
reperfusion model (10). The administration of SB225002, a
CXCR2 antagonist, was also associated with reduced
neutrophil infiltration in the brains of rats 24 h after cerebral
ischemia–reperfusion (22). Our results are in agreement
with these preliminary findings in rats (10,13). In parallel
with the decrease of PMN infiltration, as assessed by the
MPO assay, reparixin treatment decreased tissue damage
and motor compromise. Therefore, this study reinforces the
role of PMNs in stroke physiopathology and suggests that
reparixin is a promising agent for future experimental and
clinical studies. A better understanding of the mechanisms
involved in stroke pathogenesis can foster the search for
candidate drugs to prevent or attenuate the deficits caused
by cerebral ischemia. This is of paramount importance
because quality of life for stroke sufferers is largely
dependent on the severity of their motor and/or cognitive
deficits (23).
Members of the IL-1 family of cytokines, such as IL-1b, are
considered major effectors of injury in stroke. Inhibiting the
signaling of IL-1a and IL-1bwith an IL-1 receptor antagonist
was protective in experimental models of cerebral ischemia
(24). We found that reparixin-pretreated mice had lower
brain levels of IL-1b in conjunction with less structural and
functional compromise.
CXCR1/2 receptor blockade by reparixin pretreatment
resulted in a decrease of cerebral damage, as indicated by a
reduction of PMN recruitment, IL-1b levels and motor
Figure 2 - Reparixin reduces the levels of IL-1b in the brain after
middle cerebral artery occlusion/reperfusion (MCAo) in mice.
Bars represent levels of IL-1b (pg/100 mg) measured by ELISA in
the brain tissues of mice subjected or not (SHAM) to MCAo and
pretreated with vehicle or reparixin (30 mg/kg, s.c.). The results
are expressed as the means¡ SEM (n = 6). *p,0.05 compared to
Sham group. # p,0.01 compared to Vehicle. (ANOVA followed
by Newman-Keuls posthoc test).
Figure 3 - Histopathological analysis of cerebral sections of sham
(A-B), ischemia/reperfusion (C-D) and reparixin-treated mice
subjected to middle cerebral artery occlusion/reperfusion (E-F).
Hematoxylin and eosin-stained sections. Cerebral cortex of sham
mice showing normal tissue (A) and healthy neural cells (B).
Cerebral section of an ischemia/reperfusion mouse exhibits large
hemorrhagic necrosis (C). Note the inflammatory cells and
vacuolated tissue around the infarct area (D). Reparixin-treated
animals present focal infarct surrounded by ischemic neural cells
(asterisks) (E). The dotted line delineates dark and shrunken
neural cells (left) from normal neural cells (right) (F). Original
magnifications: A, C and E: x200. B, D and F: x400.
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impairment following MCAo. Further studies are needed to
determine if reparixin treatment after ischemia could
reverse the brain injury and the associated long-lasting
neurological consequences of stroke in mice. The lack of
discrimination of cortical versus subcortical damage and of
identification of the penumbra area in histopathological
analysis must be regarded as limitations of this study and
deserve further investigation.
In conclusion, these results support the concept that the
blockade of inflammatory processes mediated by CXCL8
could be a future intervention for the improvement of the
structural and behavioral consequences of human cerebro-
vascular diseases.
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Figure 4 - Reparixin prevents motor impairment after middle
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indicate levels of motor deficits as assessed by SHIRPA in mice
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pretreated with vehicle or reparixin (30 mg/kg, s.c.). The results
are expressed as the means¡ SEM (n = 6). * p,0.05 compared to
Sham group; ANOVA followed by Newman-Keuls post-test.
(ANOVA followed by Newman-Keuls posthoc test).
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